Aquestive Therapeutics Down Over 38%, on Track for Record Percent Decrease -- Data Talk

Dow Jones01-10

Aquestive Therapeutics, Inc. $(AQST)$ is currently at $3.82, down $2.39 or 38.41%

--Would be lowest close since Aug. 29, 2025, when it closed at $3.77

--Would be largest percent decrease on record (Based on available data back to July 25, 2018)

--Currently down five of the past six days

--Currently down three consecutive days; down 38.7% over this period

--Worst three day stretch since the three days ending Sept. 29, 2020, when it fell 43.39%

--Down 40.70% this week; worst weekly performance since the week ending March 13, 2020, when it fell 56.02%

--Down 40.79% month-to-date

--Down 40.79% year-to-date

--Down 79.83% from its all-time closing high of $18.96 on Sept. 7, 2018

--Up 24.19% from 52 weeks ago (Jan. 10, 2025), when it closed at $3.08

--Down 48.93% from its 52-week closing high of $7.49 on Oct. 20, 2025

--Up 72.3% from its 52-week closing low of $2.22 on May 14, 2025

--Traded as low as $3.58; lowest intraday level since July 2, 2025, when it hit $3.39

--Down 42.27% at today's intraday low; largest intraday percent decrease since March 12, 2020, when it fell as much as 45.24%

All data as of 1:07:43 PM ET

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

January 09, 2026 13:11 ET (18:11 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment